4.3. Safety of NMSs in Humans
cardiovascular disease, NMS
ADVERSE EVENTS, NMS, CARDIOVASCULAR DISEASE, DYSLIPIDEMIA
Our study reported no intervention-related adverse results throughout the investigation period, including liver function, fasting blood sugar, coagulation function, and renal function, such as blood uric acid. Although there was a between-group difference in the change in PT from baseline to 45 days, this difference was no longer statistically significant at the 120-day mark, and the PT levels remained in the reference range in both groups during the study period. Further study may be needed to study the potential mechanism. Questionnaire evaluations also revealed no notable adverse events caused by the NMS. Furthermore, dietary intake, metabolic level, and physical examination were evenly distributed between the two groups. These results support the safety of NMS supplements.In summary, we found that supplementation of NMSs significantly lowered lipid levels in patients with dyslipidemia. The results suggest that NMSs could be a safe and effective nutraceutical for reducing cardiovascular disease risk factors in patients with dyslipidemia, compared to the placebo group.